BRIEF—Microbiome treatment performs well in study

Research conducted by Brighton, UK-based Destiny Pharma, with the cooperation of the US Department of Veterans Affairs, shows successful gut colonization of its microbiome candidate NTCD-M3.

People in the study were given NTCD-M3 after treatment with the antibiotic Dificid (fidaxomicin), or pre-treatment with vancomycin, for infection with Clostridioides difficile.

The microbiome therapy is designed to prevent recurrence of infections following the normal standard-of-care antibiotic treatment, by restoring healthy bacteria to the gut.

Destiny chief executive Neil Clark said: "We are encouraged by these latest findings that support the administration of NTCD-M3 to the broadest CDI patient population receiving any approved antibiotic treatment and strengthens our planning for the NTCD-M3 Phase III study, which we aim to start later this year.”